Turner Healthcare Quality Consulting

What Turner Healthcare Quality Consulting does

Turner Healthcare Quality Consulting, Inc. (THCQ) is a privately held, minority-owned US strategic consulting firm founded in 2019 by Norris Turner, PharmD, PhD, and headquartered in Yardley, Pennsylvania. The firm advises biopharmaceutical companies of all sizes and therapeutic areas on optimizing market access, evidence generation, medical affairs, health equity, and policy/advocacy strategy through a healthcare quality and value-based care lens. THCQ applies a proprietary methodology built around the Quintuple Aim strategic framework and the WHO's seven dimensions of quality care, operationalized through cross-functional internal interviews, environmental landscape reviews, and external stakeholder engagement.

THCQ delivers its services through a three-tier engagement model: a Discovery Service Offering (DSO) entry point, a Comprehensive Quality Evaluation (CQE) scoped project, and Retainer-Based Services (RBS) available in 3-month, 6-month, and 1-year terms for ongoing advisory access. The 5-person team carries 75+ years of collective pharmaceutical and healthcare quality experience, drawing on prior tenures at Pfizer, Johnson & Johnson, Purdue Pharma, NCQA, Janssen, and the Pharmacy Quality Alliance. The firm uses a direct, consultative enterprise sales motion supplemented by content marketing, LinkedIn/Twitter presence, podcast appearances, and industry conference participation (IVI, PQA, WorldUpstart).

Named current and past clients include Bayer, Takeda, PhRMA, Genomind, ESPhA, and RxE2. THCQ has no disclosed institutional funding, operates as a bootstrapped boutique with a single US location, and has no software products, APIs, or proprietary technology platform; revenue is generated entirely through fee-for-service and retainer consulting engagements with custom, undisclosed pricing.

Name

Turner Healthcare Quality Consulting

Legal name

Turner Healthcare Quality Consulting, Inc.

Website

https://thcqconsulting.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Turner Healthcare Quality Consulting is a US boutique consulting firm that advises biopharmaceutical companies on market access, evidence generation, medical affairs, health equity, and policy strategy through a healthcare quality and value-based care lens, delivering project-based and retainer advisory services from a 5-person team.

Ownership category

akta.pro rank

Product category

Healthcare Quality Consulting

NAICS

Management Consulting Services (54161), Other Management Consulting Services (541618)

SIC

Services-Management Consulting Services (8742), Services-Health Services (8000)

akta.pro primary industry

Quality Measurement, Reporting & Benchmarking (HEDIS/Stars/CQM) (HLACAHAC)

akta.pro secondary industries

KOL Engagement & Medical Education (Advisory Boards/CME Support) (HLAGALAM), Organization Design & Operating Model Consulting (BPAHAGAB)

Keywords

• Healthcare quality consulting
• Biopharma market access strategy
• Value-based care advisory
• Medical affairs consulting
• Pharmaceutical strategic consulting

Headquarters

HQ city

Yardley

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Strategic Consulting Services: THCQ generates revenue through fee-for-service consulting engagements structured in three tiers: Discovery Service Offering (DSO), Comprehensive Quality Evaluation (CQE), and Retainer-Based Services (RBS). RBS provides ongoing strategic advisory access for set terms (3 months, 6 months, 1 year). Services are customized for biopharma clients in medical affairs, evidence generation strategy, market access, health equity, and policy & advocacy.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

Turner Healthcare Quality Consulting provides strategic advisory services to biopharmaceutical companies, structured as three tiers: a Discovery Service Offering (DSO) entry engagement, a Comprehensive Quality Evaluation (CQE) scoped project with cross-functional interviews and landscape review, and Retainer-Based Services (RBS) for ongoing advisory in 3-, 6-, and 12-month terms. Engagements apply the Quintuple Aim strategic lens and healthcare quality frameworks to medical affairs, evidence generation, market access, health equity, and policy and advocacy challenges for biopharma clients across all therapeutic areas.

Product overview

Turner Healthcare Quality Consulting offers a portfolio of strategic consulting services focused on helping biopharmaceutical companies optimize their market access strategy through a healthcare quality lens. The core offerings consist of three service models: Discovery Service Offering (DSO) as an entry point, Comprehensive Quality Evaluation (CQE) as the primary customized consulting engagement, and Retainer-Based Services (RBS) for ongoing advisory support. Services span medical affairs, evidence generation strategy, market access, health equity, and policy & advocacy. These services help clients understand customer healthcare quality and value-based care perspectives to deliver better patient outcomes, improve experiences, reduce costs, and advance health equity.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• Developed 19 actionable recommendations in 6 project domains for a client's Medical Affairs Field stakeholder engagement plan
• +2 more outcomes

Named customers6 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered minor.

• WorldUpstartminorGTM or Marketing Partner · 1 January 2023THCQ President & CEO Norris Turner participated in a WorldUpstart panel discussion titled 'Trends in Life Sciences and MedTech in the US' in 2023. The partnership involved an interview published on the WorldUpstart blog and a panel appearance, positioning THCQ within the global life sciences and MedTech startup ecosystem.
• Innovation and Value Initiative (IVI)minorOthers · 1 January 2023THCQ President & CEO Norris Turner served as a speaker at the 2023 IVI Annual Meeting, the formal convening of IVI members to engage in productive and action-focused discussions on how value is defined in healthcare. This positions THCQ within the healthcare value measurement and value-based care research community.
• Pharmacy Quality Alliance (PQA)minorOthers · 1 January 2023THCQ President & CEO Norris Turner was a panelist for the PQA Quality Forum titled 'Diverse Voices in Quality', a recurring webinar series on healthcare quality topics focused on educating and engaging PQA members and quality-focused healthcare professionals. Norris previously worked at PQA, where he gained expertise in quality measure development.
• SemalytixminorStrategic or Co-development PartnerTHCQ Consulting has a formal partnership with Semalytix, an innovative data science company that enables research-curated gathering of patient insights at scale. This partnership supports THCQ's patient-centeredness work by providing data-driven patient insight capabilities. Full disclosure is noted on the THCQ website.
• ESPhAminorStrategic or Co-development PartnerESPhA is a consulting firm that utilizes THCQ consulting services for healthcare quality strategy support. Tripp Logan, PharmD, Partner at ESPhA, stated that since utilizing THCQ, the team has been 'blown away' by the valuable insights provided. THCQ functions as a sub-consultant or strategic partner to ESPhA's consulting engagements.
• RxE2minorImplementation/ SI/ Consulting PartnerTHCQ provided retainer-based expert advisory services to RxE2, a startup focused on independent community pharmacy networks for clinical trial recruitment. Services included strategic support for recruitment messaging, operational aspects of the community pharmacy network, and advisory for establishing a community pharmacy and pharmaceutical company data-sharing pilot for diverse patient recruitment into clinical trials.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Avalere Health: Healthcare-focused strategy and policy advisory firm serving biopharma, payers, and providers on market access, evidence generation, and value-based care. Highly comparable in buyer persona (biopharma medical affairs and market access teams), service mix, and policy/quality lens.
• Discern Health (now part of Real Chemistry): Specialty healthcare consulting firm focused on quality measurement, value-based care, and population health — explicitly founded on quality-measurement frameworks used by NCQA. THCQ team member Manasi Tirodkar is a Discern Health alumna, underscoring direct comparability.
• Precision Medicine Group (Precision Advisors): Specialty biopharma services firm with advisory offerings in medical affairs, market access, and evidence generation. Highly comparable buyer persona (cross-functional biopharma leadership) and strategic-advisory delivery model.

Broad incumbents

• BCG (Healthcare Practice): Top-tier strategy consultancy with dedicated biopharma and value-based-care practices. Competes for similar enterprise advisory budgets with broader service portfolio and global delivery.
• McKinsey & Company (Pharma & Medical Products Practice): Global strategy consulting firm with a large pharma and medical products practice covering market access, value-based care, and commercial strategy. Competes for senior pharma advisory engagements but at much larger scale and broader mandate.
• IQVIA (Consulting Services): Largest life-sciences data and advisory platform, with a consulting arm serving biopharma on commercial, medical affairs, and value-based-care strategy. Comparable in buyer and topic; far broader in offerings and scale.
• Syneos Health Consulting: Biopharma-focused contract research and commercial organization with a consulting arm advising on medical affairs, market access, and value-based care. Comparable in buyer and topic area, with materially larger delivery footprint.
• ZS Associates: Large global consulting firm with a deep biopharma practice covering market access, medical affairs, and evidence strategy. Competes for similar pharma advisory budgets but at significantly greater scale and broader scope than THCQ.
• Xcenda (AmerisourceBergen / Cencora): Consulting arm of a major pharma services distributor, advising biopharma on market access, health economics, and value-based contracting. Directly comparable on value-based-care and market-access advisory scope for biopharma clients.
• Evidera (PPD, part of Thermo Fisher): Health economics, outcomes research, and market access consulting firm serving biopharma on evidence generation and value-based-care strategy. Comparable in functional buyer (HEOR, market access) and value-based-care advisory delivery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/thcqconsulting
• LinkedInlinkedin.com/company/thcq

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Turner Healthcare Quality Consulting